Document Detail

A 13-years remission in chronic myelocytic leukemia after a single course of busulfan.
MedLine Citation:
PMID:  97894     Owner:  NLM     Status:  MEDLINE    
A patient with chronic myelocytic leukemia in whom a clinical and hematological remission occurred after a single course of busulfan is described. The remission lasted for a period of 13 years and during that lapse of time, she gave birth to a healthy child. Afterwards, acute myeloblastic leukemia was diagnosed. Following treatment with rubidomycin and arabinoside C another remission was achieved, lasting already for 18 months.
A Weinberger; D Benjamin; D Douer; G Barabash; M Djaldetti; J Pinkhas
Related Documents :
24980644 - What are the factors that affect survival and relapse after local recurrence of osteosa...
19404024 - bacillus cereus sepsis and subarachnoid hemorrhage following consolidation chemotherapy...
25101264 - The role of narrow band imaging in the detection of recurrent laryngeal and hypopharyng...
6295134 - Acute leukemia after successful chemotherapy for oat cell carcinoma.
22808294 - High expression level of blca-4 correlates with poor prognosis in human bladder cancer.
21609654 - Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refra...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Acta haematologica     Volume:  59     ISSN:  0001-5792     ISO Abbreviation:  Acta Haematol.     Publication Date:  1978  
Date Detail:
Created Date:  1978-09-30     Completed Date:  1978-09-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0141053     Medline TA:  Acta Haematol     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  354-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Busulfan / therapeutic use*
Cytarabine / therapeutic use
Daunorubicin / therapeutic use
Leukemia, Myeloid / drug therapy*
Leukemia, Myeloid, Acute / drug therapy
Remission, Spontaneous
Time Factors
Reg. No./Substance:
147-94-4/Cytarabine; 20830-81-3/Daunorubicin; 55-98-1/Busulfan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Congenital methemoglobin-reductase (cytochrome b5 reductase) deficiency associated with mental retar...
Next Document:  Interaction between iron deficiency and alpha-thalassaemia: the in vitro effect of haemin on alpha-c...